Raras
Buscar doenças, sintomas, genes...
Espectro clínico de neuromielite óptica com anticorpos anti-MOG
ORPHA:592856CID-10 · G36.0CID-11 · 8A41.1PCDT · SUSDOENÇA RARA
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Transtornos do espectro da neuromielite óptica (NMOSD) são um espectro de doenças autoimunes caracterizadas por inflamação aguda do nervo óptico e da medula espinhal (mielite). Os episódios de neurite óptica (ON) e mielite podem ser simultâneos ou sucessivos. Um curso da doença com recidivas é comum, especialmente em pacientes não tratados. Neuromielite óptica (NMO) é uma doença particular dentro do espectro da NMOSD. É caracterizada por neurite óptica e mielite longitudinalmente extensa. Em mais de 80% dos casos de NMO, a causa são autoanticorpos de imunoglobulina G contra a aquaporina 4 (anti-AQP4), a proteína de canal de água mais abundante no sistema nervoso central.

🏥
SUS: Cobertura parcialScore: 65%
PCDT disponível4 medicamentos CEAFCID-10: G36.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Últimos 10 anos145publicações
Pico201921 papers
Linha do tempo
20202015Hoje · 2026📈 2019Ano de pico🧪 2025Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Espectro clínico de neuromielite óptica com anticorpos anti-MOG

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Rare demyelinating diseases of the central nervous system: A diagnostic and therapeutic challenge - based on the case of a young woman with MOGAD.

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego2026

Demyelinating diseases of the central nervous system constitute a heterogeneous group of diseases. The best known is multiple sclerosis, while neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare diseases. A 19-year-old female patient was admitted to the neurology department due to rapidly progressing memory and speech disorders. Mild mixed aphasia and right-sided pyramidal syndrome were diagnosed. Magnetic resonance imaging (MRI) of the brain revealed acute nodular demyelination in the left hemisphere. Intravenous methylprednisolone was administered. After approximately 2 months, the patient was readmitted due to several generalized epileptic seizures. At that time, the patient was transferred to a clinical center, where extensive diagnostics was performed. Among others, acute disseminated encephalitis, autoimmune encephalitis, tumefactive multiple sclerosis, and tumor were taken into consideration. MRI with spectroscopy and angiography revealed degenerative changes following acute demyelination. General examination of the cerebrospinal fluid was normal. No anti-neuronal antibodies were detected. However, positive anti-MOG antibodies were detected (and antibodies against aquaporin 4 were negative), which led to a suspicion of MOGAD. The patient was discharged home with a recommendation to use antiepileptic drugs and oral steroids. It is important to remember about rare demyelinating diseases, such as MOGAD, which require differentiation from multiple sclerosis. The prognosis for this condition is generally better, but the disease can lead to permanent neurological damage.

#2

Double Anti-NMO and Anti-MOG Positivity in a Patient With Metastatic Renal Carcinoma: First Reported Case.

Case reports in neurological medicine2026

Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are central nervous system (CNS) demyelinating disorders characterized by autoantibodies targeting aquaporin-4 (AQP4) and MOG, respectively. Although dual positivity for AQP4-IgG and MOG-IgG antibodies is uncommon, it poses significant diagnostic and therapeutic challenges due to its complex clinical features and uncertain prognosis. We present the first reported case in the literature of a patient with metastatic renal carcinoma who tested positive for both AQP4 and MOG antibodies. A 49-year-old man with a history of metastatic renal carcinoma experienced progressive neurological symptoms, initially attributed to tumor progression. However, after further investigation, including lumbar puncture and autoantibody testing, a demyelinating process with dual seropositivity for AQP4-IgG and MOG-IgG was identified. The patient was treated with high-dose corticosteroids, followed by rituximab, resulting in clinical and radiological stability. This case highlights the rare occurrence of dual seropositivity for AQP4 and MOG antibodies in a patient with a history of metastatic renal carcinoma, which poses diagnostic and treatment challenges. Although the pathogenesis remains unclear, factors such as genetic predisposition and autoimmune coactivation may contribute to triggering this autoimmune response. This case emphasizes the importance of personalized treatment and the need for further research to optimize management strategies for patients with this complex condition.

#3

Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.

BMC neurology2025 Nov 12

Double seronegative neuromyelitis optica spectrum disorder (DN-NMOSD) is a rare autoimmune disease of the central nervous system, typically involving the optic nerve and spinal cord, characterized by negativity for anti-AQP4 and anti-MOG antibodies. A 35-year-old man with optic neuritis and recurrent myelitis, negative for AQP4 and MOG antibodies, was diagnosed with double seronegative NMOSD (DN-NMOSD). Initial treatment with Rituximab led to temporary stability, but relapses in 2021 and 2022 prompted a switch to Satralizumab (anti-IL-6R), achieving two years of clinical and radiological stability. This case underscores the therapeutic potential of anti-IL-6 drugs for DN-NMOSD, especially when anti-CD20 therapies fail. It highlights the heterogeneity of DN-NMOSD and the need for novel biomarkers, such as GFAP, tau, and IL-6, to better understand disease mechanisms and guide targeted treatments. A structured therapeutic approach, starting with anti-CD20 drugs and progressing to anti-IL-6 agents if ineffective, may optimize outcomes in this poorly understood condition.

#4

Coronavirus Disease 2019 Infection and Vaccination in Pediatric Demyelinating Diseases.

Pediatric neurology2025 Jul

As compared to adults, less is known about the effects of SARS-CoV-2 infection in children with neuroinflammatory diseases, such as multiple sclerosis (MS), anti-myelin oligodendrocyte glycoprotein associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD). Moreover, the effects of SARS-CoV-2 vaccination on pediatric demyelinating diseases is also lesser known. Here, we examine the effects of SARS-CoV-2 infection and vaccination on children with demyelinating diseases. Retrospective chart review was performed at a single tertiary pediatric center, including 116 children with demyelinating diagnoses (MOGAD, MS, NMOSD, transverse myelitis-TM, and acute disseminated encephalomyelitis). Descriptive statistics and logistic regression were used. The diagnoses included: MS: 56/116 = 48%, MOGAD: 32/116 = 28%, NMOSD: 15/116 = 13%, acute disseminated encephalomyelitis: 12/116 = 10%, and TM: 1/116 = 1%. The known COVID infection rate was 26% = 30/116. Three of 30 (10%) of those with known infection were hospitalized. None of those hospitalized required intubation or ICU admission. Of the 30 with known infection, two (7%) had neuroinflammatory events that occurred within four weeks of infection, both of which were their first clinical events for MS. SARS-CoV-2 vaccination was not associated with any new onset or relapse neuroinflammatory events in our cohort. Demyelinating diagnosis and anti-CD20 mAbs were associated with known SARS-CoV-2 infection. Two participants had an initial clinical MS event associated with infection. However, we found no association with SARS-COV-2 vaccination or infection with relapses and no long-term adverse outcomes with SARS-CoV-2 vaccination or infection. Future larger multicenter studies should prospectively compare how infection and vaccination affects children and adults with demyelinating diseases.

#5

Confusing Onset of MOGAD in the Form of Focal Seizures.

Neurology international2025 Feb 27

MOGAD is a demyelinating syndrome with the presence of antibodies against myelin oligodendrocyte glycoprotein, which is, next to multiple sclerosis and the neuromyelitis optica spectrum, one of the manifestations of the demyelinating process, more common in the pediatric population. MOGAD can take a variety of clinical forms: acute disseminated encephalomyelitis (ADEM), retrobulbar optic neuritis, often binocular (ON), transverse myelitis (TM), or NMOSD-like course (neuromyelitis optica spectrum disorders), less often encephalopathy. The course may be monophasic (40-50%) or polyphasic (50-60%), especially with persistently positive anti-MOG antibodies. Very rarely, the first manifestation of the disease, preceding the typical symptoms of MOGAD by 8 to 48 months, is focal seizures with secondary generalization, without typical demyelinating changes on MRI of the head. The paper presents a case of a 17-year-old patient whose first symptoms of MOGAD were focal epileptic seizures in the form of turning the head to the right with the elevation of the left upper limb and salivation. Seizures occurred after surgical excision of a tumor of the right adrenal gland (ganglioneuroblastoma). Then, despite a normal MRI of the head and the exclusion of onconeural antibodies in the serum and cerebrospinal fluid after intravenous treatment, a paraneoplastic syndrome was suspected. After intravenous steroid treatment and immunoglobulins, eight plasmapheresis treatments, and the initiation of antiepileptic treatment, the seizures disappeared, and no other neurological symptoms occurred for nine months. Only subsequent relapses of the disease with typical radiological and clinical picture (ADEM, MDEM, recurrent ON) allowed for proper diagnosis and treatment of the patient both during relapses and by initiating supportive treatment. The patient's case allows us to analyze the multi-phase, clinically diverse course of MOGAD and, above all, indicates the need to expand the diagnosis of epilepsy towards demyelinating diseases: determination of anti-MOG and anti-AQP4 antibodies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 144

2026

Rare demyelinating diseases of the central nervous system: A diagnostic and therapeutic challenge - based on the case of a young woman with MOGAD.

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
2026

Double Anti-NMO and Anti-MOG Positivity in a Patient With Metastatic Renal Carcinoma: First Reported Case.

Case reports in neurological medicine
2025

Multifocal Presentations of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Case Series From a District General Hospital in South East England.

Cureus
2025

Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.

BMC neurology
2025

[Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): What controversies remain?].

Medicina
2025

An Emerging Autoimmune Neuroinflammatory Disease: Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Annals of African medicine
2025

French guidelines for the diagnosis and management of MOG antibody-associated disease.

Revue neurologique
2025

Coronavirus Disease 2019 Infection and Vaccination in Pediatric Demyelinating Diseases.

Pediatric neurology
2025

Herpes Zoster Myelitis Mimicking Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease: A Case Report.

Cureus
2025

Confusing Onset of MOGAD in the Form of Focal Seizures.

Neurology international
2025

Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients.

Scientific reports
2024

New-Onset Multiple Sclerosis in Pregnancy: Diagnostic Approaches and Treatment Dilemmas.

Cureus
2024

The Varying Faces of MOGAD: A Case Series.

Annals of African medicine
2024

Polyautoimmunity and multiple autoimmune syndrome in patients with neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders
2024

A rare case of systemic lupus erythematosus-associated neuromyelitis optica spectrum disorder with cystic lesions and dual seropositivity for anti-AQP4 and anti-MOG antibodies.

Clinical case reports
2024

Reversible Bilateral Vision Loss: An Unusual Presentation of Wernicke-Korsakoff Syndrome.

Cureus
2024

Indirect Immunofluorescence-Aided Detection of Antimyelin Oligodendrocyte Glycoprotein Antibodies in Neuromyelitis Optica Spectrum Disorder/Myelin Oligodendrocyte Glycoprotein-Associated Antibody Disorder: A Case Series Involving Five Patients.

Annals of African medicine
2024

MOG CNS Autoimmunity and MOGAD.

Neurology(R) neuroimmunology & neuroinflammation
2024

Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease.

Cureus
2024

Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein.

Balkan medical journal
2024

[Anti-MOG associated disease].

Revue medicale suisse
2024

Clinical Research into Central Nervous System Inflammatory Demyelinating Diseases Related to COVID-19 Vaccines.

Diseases (Basel, Switzerland)
2024

An aggressive form of MOGAD treated with aHSCT: A case report.

Multiple sclerosis (Houndmills, Basingstoke, England)
2023

Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience.

Arquivos de neuro-psiquiatria
2023

Understanding MOG antibody-associated disease in Brazil.

Arquivos de neuro-psiquiatria
2023

Dual positivity for anti-MOG and oligoclonal bands: Unveiling unique clinical profiles and implications.

Multiple sclerosis and related disorders
2023

Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review.

International journal of molecular sciences
2023

Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report.

Frontiers in neuroscience
2023

Paracentral Acute Middle Maculopathy Associated with Severe Anti-Mog (Myelin Oligodendrocyte Glycoprotein)-Positive Optic Neuritis.

Neuro-ophthalmology (Aeolus Press)
2023

Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2023

A comparative analysis of demographic, clinical and imaging features of myelin oligodendrocyte glycoprotein antibody positive, aquaporin 4 antibody positive, and double seronegative demyelinating disorders - An Indian tertiary care center prospective study.

Journal of neurosciences in rural practice
2023

Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.

Multiple sclerosis and related disorders
2023

Myelin oligodendrocyte glycoprotein antibody-associated disease in children: Are there MRI predictors of relapse?

Journal of neuroradiology = Journal de neuroradiologie
2023

A Quality Assessment of Aquaporin-4 & Myelin Oligodendrocyte Glycoprotein Antibody Testing.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2022

Area Postrema Syndrome: An Initial Presentation of Double-Seropositive AQP4 and MOG Antibodies.

Neurology. Clinical practice
2022

Double seropositive neuromyelitis optica associated with COVID-19: A case report.

Frontiers in neurology
2022

The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives.

Multiple sclerosis and related disorders
2022

Neuromyelitis optica spectrum disorder with negative aquaporin-4 antibodies and positive anti-myelin oligodendrocyte glycoprotein antibodies: A case report.

Medical journal, Armed Forces India
2022

Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2022

Myelin Oligodendrocyte Glycoprotein-Associated Disorders.

Continuum (Minneapolis, Minn.)
2022

Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies.

International journal of ophthalmology
2022

Comparison of Clinical and Radiological Features of Aquaporin4 (AQP-4) Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) and Anti Myelin Oligodendrocyte Glycoprotein (Anti-MOG) Syndrome-Our Experience from Northwest India.

Annals of Indian Academy of Neurology
2022

Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups.

Multiple sclerosis and related disorders
2022

Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2022

Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.

Journal of the neurological sciences
2022

Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study.

Neurology international
2022

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.

Journal of neuroinflammation
2022

Update on Optic Neuritis: An International View.

Neuro-ophthalmology (Aeolus Press)
2022

Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study.

Multiple sclerosis and related disorders
2021

Acute Demyelinating Syndromes: A report of child neurology department of Sfax University Hospital.

Multiple sclerosis and related disorders
2021

Recurrent Bilateral Optic Neuritis Associated with Myelin Oligodendrocyte Glycoprotein Antibody: A Case Report from Nepal.

Case reports in neurological medicine
2021

Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.

Multiple sclerosis and related disorders
2021

Myelin-oligodendrocyte glycoprotein antibody-associated disease.

The Lancet. Neurology
2022

Application of deep-learning to the seronegative side of the NMO spectrum.

Journal of neurology
2021

Conus medullaris involvement in demyelinating disorders of the CNS: A comparative study.

Multiple sclerosis and related disorders
2021

Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review.

Journal of neuroimmunology
2021

MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.

Brain : a journal of neurology
2021

[Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease].

Brain and nerve = Shinkei kenkyu no shinpo
2021

No strong HLA association with MOG antibody disease in the UK population.

Annals of clinical and translational neurology
2021

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.

Neurology
2021

Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: A case report.

Medicine
2022

Hemicraniectomy and externalized ventricular drain placement in a pediatric patient with myelin oligodendrocyte glycoprotein-associated tumefactive demyelinating disease.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2021

Progressive Leukodystrophy-Like Demyelinating Syndromes with MOG-Antibodies in Children: A Rare Under-Recognized Phenotype.

Neuropediatrics
2021

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method.

Frontiers in neurology
2021

Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report.

BMC neurology
2021

The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey.

International journal of clinical practice
2020

Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis.

Journal of ophthalmology
2021

Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.

Multiple sclerosis and related disorders
2021

Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.

Journal of neuroimmunology
2021

MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review.

Lupus
2020

Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany.

Journal of neurology, neurosurgery, and psychiatry
2020

Atypical Multiple Sclerosis with Antibody to MOG.

Neurology India
2020

Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases.

Journal of the neurological sciences
2020

Clinical outcomes of transverse myelitis with myelin oligodendrocyte glycoprotein antibody versus negative cases among adults in Isfahan, Iran: A comparative study.

Current journal of neurology
2021

An update on epidemiology, diagnosis & management of NMO-SD in the tertiary neurology department of Marrakech (Morocco).

Revue neurologique
2021

Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders.

Cellular & molecular immunology
2021

[Atypical optic neuritis: the importance of a comprehensive diagnostic work-up].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
2020

Autoimmune and demyelinating optic neuritis.

Archivos de la Sociedad Espanola de Oftalmologia
2020

Unilateral Optic Neuritis in Children: Experience of a Tertiary Centre.

European neurology
2020

Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis.

Multiple sclerosis and related disorders
2020

Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum.

Frontiers in neurology
2020

A Fulminant Case of Demyelinating Encephalitis With Extensive Cortical Involvement Associated With Anti-MOG Antibodies.

Frontiers in neurology
2020

[Anti-myelin oligodendrocyte glycoprotein antibody-positive neurologic disease, manifested as clinical course of classical Devic's disease: A case report].

Rinsho shinkeigaku = Clinical neurology
2020

Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.

The Lancet. Neurology
2020

Use of ganglion cell layer analysis for diagnosing anti-glycoprotein neuromyelitis optica of oligodendrocyte myelin.

Archivos de la Sociedad Espanola de Oftalmologia
2020

[Anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis].

Rinsho shinkeigaku = Clinical neurology
2020

Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays.

Journal of the neurological sciences
2020

Neuromyelitis Optica Spectrum Disorder and Anti-Aquaporin 4 Channel Immunoglobulin in an Australian Pediatric Demyelination Cohort.

Journal of child neurology
2019

[Optic neuropathy in positive anti-MOG antibody syndrome].

Journal francais d'ophtalmologie
2020

CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research
2019

Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis.

Current opinion in ophthalmology
2019

The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement.

Journal of neuroimmunology
2019

A young woman with seizures, visual impairment, and paralysis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
2019

A unique case of multiphasic ADEM or what else?

Multiple sclerosis and related disorders
2019

Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet's disease.

Journal of neuroimmunology
2019

Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.

Multiple sclerosis and related disorders
2019

MRI features of demyelinating disease associated with anti-MOG antibodies in adults.

Journal of neuroradiology = Journal de neuroradiologie
2019

Optic neuritis, encephalitis and leptomeningeal enhancement in a patient with anti-MOG antibodies: A case study.

Multiple sclerosis and related disorders
2019

Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes.

Biomedicines
2019

The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.

Multiple sclerosis and related disorders
2019

Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease.

Multiple sclerosis and related disorders
2019

Antibody-mediated biorecognition of myelin oligodendrocyte glycoprotein: computational evidence of demyelination-related epitopes.

Scientific reports
2019

Live-cell based assays are the gold standard for anti-MOG-Ab testing.

Neurology
2020

Anti-MOG Antibody Seropositive Neuromyelitis Optica: A Rare Pediatric Case.

Noro psikiyatri arsivi
2019

Astrocytic damage in glial fibrillary acidic protein astrocytopathy during initial attack.

Multiple sclerosis and related disorders
2019

Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.

Multiple sclerosis and related disorders
2019

Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD).

Multiple sclerosis and related disorders
2018

[Clinical analysis of opticospinal multiple sclerosis (OSMS) presentation detecting anti-myelin oligodendrocyte glycoprotein (MOG) antibody].

Rinsho shinkeigaku = Clinical neurology
2019

Positive anti-MOG antibodies in a patient with Sjögren's syndrome and transverse myelitis.

European journal of rheumatology
2019

Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome.

Multiple sclerosis and related disorders
2019

Inflammatory demyelinating diseases of the central nervous system in Niger.

Revue neurologique
2018

Clinical utility of anti-MOG antibody testing in a Danish cohort.

Multiple sclerosis and related disorders
2018

NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report.

Multiple sclerosis and related disorders
2018

Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.

Multiple sclerosis and related disorders
2018

Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases.

Pediatric neurology
2018

MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response.

Multiple sclerosis journal - experimental, translational and clinical
2018

Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder.

Multiple sclerosis (Houndmills, Basingstoke, England)
2018

An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis.

Journal of neuroimmunology
2018

[Autoantibodies in Neuromyelitis Optica Spectrum Disorders].

Brain and nerve = Shinkei kenkyu no shinpo
2018

Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Therapeutic advances in neurological disorders
2018

Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome.

European journal of neurology
2017

Anti Myelin Oligodendrocyte Glycoprotein associated Immunoglobulin G (AntiMOG-IgG)-associated Neuromyelitis Optica Spectrum Disorder with Persistent Disease Activity and Residual Cognitive Impairment.

Annals of Indian Academy of Neurology
2017

[Anti-MOG Antibody Associated Diseases].

Brain and nerve = Shinkei kenkyu no shinpo
2017

Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.

Journal of neuroimmunology
2018

Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?

Arthritis & rheumatology (Hoboken, N.J.)
2017

[A case of recurrent myelitis associated with anti-myelin oligodendrocyte glycoprotein antibody that developed only as localized short spinal cord lesions].

Rinsho shinkeigaku = Clinical neurology
2017

A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection.

Multiple sclerosis and related disorders
2017

[Neuromyelitis optica with anti-MOG antibodies: A case report].

Journal francais d'ophtalmologie
2017

Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis.

Journal of child neurology
2017

Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination.

Journal of neuroinflammation
2017

The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.

Brain sciences
2017

[An asynchronous bilateral optic neuropathy with positive MOG antibodies].

Journal francais d'ophtalmologie
2017

Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report.

BMC neurology
2016

Serological markers associated with neuromyelitis optica spectrum disorders in South India.

Annals of Indian Academy of Neurology
2016

Different etiologies and prognoses of optic neuritis in demyelinating diseases.

Journal of neuroimmunology
2016

[Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis].

No to hattatsu = Brain and development
2016

Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.

Journal of neuroimmunology
2016

Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.

Acta neuropathologica
2016

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

Science China. Life sciences
2016

Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.

Autoimmunity reviews
2016

Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.

Multiple sclerosis (Houndmills, Basingstoke, England)
2016

The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.

Multiple sclerosis (Houndmills, Basingstoke, England)
2015

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Journal of neuroinflammation
2015

Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis.

BMJ open

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Espectro clínico de neuromielite óptica com anticorpos anti-MOG.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Espectro clínico de neuromielite óptica com anticorpos anti-MOG

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Rare demyelinating diseases of the central nervous system: A diagnostic and therapeutic challenge - based on the case of a young woman with MOGAD.
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego· 2026· PMID 41746891mais citado
  2. Double Anti-NMO and Anti-MOG Positivity in a Patient With Metastatic Renal Carcinoma: First Reported Case.
    Case reports in neurological medicine· 2026· PMID 41608319mais citado
  3. Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.
    BMC neurology· 2025· PMID 41225357mais citado
  4. Coronavirus Disease 2019 Infection and Vaccination in Pediatric Demyelinating Diseases.
    Pediatric neurology· 2025· PMID 40367669mais citado
  5. Confusing Onset of MOGAD in the Form of Focal Seizures.
    Neurology international· 2025· PMID 40137458mais citado
  6. [Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): What controversies remain?].
    Medicina (B Aires)· 2025· PMID 41036985recente
  7. French guidelines for the diagnosis and management of MOG antibody-associated disease.
    Rev Neurol (Paris)· 2025· PMID 40494723recente
  8. Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients.
    Sci Rep· 2025· PMID 39789036recente
  9. Polyautoimmunity and multiple autoimmune syndrome in patients with neuromyelitis optica spectrum disorder.
    Mult Scler Relat Disord· 2024· PMID 39236487recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:592856(Orphanet)
  2. MONDO:0035664(MONDO)
  3. Neuromielite Optica(PCDT · Ministério da Saúde)
  4. GARD:22373(GARD (NIH))
  5. Busca completa no PubMed(PubMed)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Espectro clínico de neuromielite óptica com anticorpos anti-MOG
Compêndio · Raras BR

Espectro clínico de neuromielite óptica com anticorpos anti-MOG

ORPHA:592856 · MONDO:0035664
🇧🇷 Brasil SUS
CEAF
1AEculizumabeRavulizumabeSatralizumabeInebilizumabe
Geral
CID-10
G36.0 · Neuromielite óptica [doença de Devic]
CID-11
MedGen
UMLS
C5680296
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades